TD Cowen's Dan Brennan was the most conservative of the trio, as he bumped his fair value assessment higher to $118 per share from his previous$110 while maintaining his buy recommendation. Wells Fargo pundit Brandon Couillard remains more cautious, as he kept his equal weight (read: hold) designation intact but lifted his price target to $95 per share from$78. GeneDx's second-quarter earnings release showed not only a vast improvement in revenue and a flip into the black on the bottom line, but those fun ...